Home

Concept Medical has announced the enrolment of the first patient in the FUTURE BTK (Randomised controlled trial of first sirolimus-coated balloon versus standard balloon angioplasty in the treatment of below-the-knee artery disease) trial. The index patient was successfully enrolled on 26 August 2020 in Singapore.

FUTURE BTK is a randomised, double-blind, placebo-controlled, multicentere trial. It is aimed at determining the effectiveness of MagicTouch PTA sirolimus-coated balloon versus standard balloon angioplasty for the treatment of below the knee arterial disease in chronic limb-threatening ischaemia (CLTI) patients.

Sirolimus-coated balloons are considered to be the next new generation of drug-coated balloons (DCBs), and MagicTouch PTA sirolimus-coated balloon offers a solution which optimises both the deliverability and the absorption of sirolimus into the vessel wall.

Edward Choke (Sengkang General Hospital, Singapore, Singapore), principal investigator of FUTURE-BTK comments: “CLTI is a condition which puts patients at an increased risk of limb amputation and death. Its burden is likely to grow in the coming years given the rising trends in key risk factors such as age and diabetes. Effective revascularisation is the cornerstone of treatment, but this is often hampered by high rates of restenosis and reintervention after conventional balloon angioplasty”.

He adds: “The novel MagicTouch PTA sirolimus-coated balloon has emerged as one of the most promising transcatheter technologies in preventing restenosis for below-the-knee lesions. The earlier data on the efficacy of MagicTouch PTA from small studies are encouraging but these need to be confirmed or refuted. I look forward to the FUTURE BTK randomised controlled trial, which will test whether the MagicTouch PTA sirolimus-coated balloon can improve the patency of below-the-knee arteries in CLTI patients, and this will hopefully bring us closer to our goal of reducing leg amputations”.

The trial will enrol 210 patients with Rutherford class 4 to 6 CLTI. These subjects will be randomised in 2:1 fashion to receive either MagicTouch PTA or standard balloon angioplasty. Primary outcome will be primary patency at six months, defined as duplex peak systolic velocity ratio (PSVR) of 2.4 or less.

The trial is designed to follow a rigorous blinding protocol in order to minimise bias. Patients, care providers, investigators, and outcome assessors, including vascular technologists performing the duplex ultrasound, will be blinded to the treatment allocations. The patients will be followed up for two years.

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua google bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua twitter bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua MySpace bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua LinkedIn bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua stumbleupon bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua icio bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua digg bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Chia sẽ qua yahoo bài: Enrolment initiated in world’s first RCT with sirolimus-coated balloon for below-the-knee PAD treatment

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.